Pfiz­er de­tails mR­NA flu vac­cine da­ta, but re­vis­es time­line

Pfiz­er’s mR­NA flu vac­cine met both pri­ma­ry end­points in the 18- to 64-year-old pop­u­la­tion in an on­go­ing Phase III tri­al, the com­pa­ny an­nounced on Tues­day morn­ing. How­ev­er, ex­ec­u­tives are no longer shoot­ing for a 2024 launch.

While Pfiz­er ini­tial­ly pegged a pos­si­ble 2024 launch for its stand­alone mR­NA flu vac­cine, that tim­ing has been pushed to “af­ter 2024.” Its next-gen­er­a­tion mR­NA flu and Covid-19 com­bi­na­tion vac­cine is ex­pect­ed to launch in 2025, CEO Al­bert Bourla said in pre­pared re­marks ahead of the com­pa­ny’s third-quar­ter earn­ings call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.